Core Insights - Health Road Co., Ltd. has entered the cell therapy field through a strategic partnership with He Yuan Biotechnology (Shanghai) Co., Ltd., marking a significant step in building a comprehensive health service ecosystem [1] - The collaboration with He Yuan Biotechnology, a company listed on the STAR Market, enhances Health Road's capabilities in the cell and gene therapy sector, leveraging He Yuan's integrated platform for research, production, and application [1] - Health Road's existing digital health service platform, with 211.8 million registered users and 905,000 registered doctors, aligns well with the new focus on cell storage, preparation, and exosome preparation [1] Business Model and Strategy - On the B2B side, Health Road has established a network covering over 11,000 medical institutions, enhancing customer loyalty and service value through cell technology support [2] - For the C2C segment, the company plans to introduce innovative product combinations such as "cell storage + health assessment" and "exosome anti-aging + medical health services" to maximize user lifecycle value [2] - The enterprise service segment aims to design innovative products like "insurance + cell therapy" for partners in insurance and banking, further extending the service chain [2] Competitive Advantage - The synergistic effect of this strategy allows Health Road to leverage existing resources for rapid expansion without the need to build clinical channels and user trust from scratch [2] - The strategic positioning in the cell biotechnology sector is seen as forward-looking, utilizing a light asset and strong synergy model to avoid heavy R&D investment risks while maximizing existing ecosystem advantages [2] - As the business model is validated and implemented, Health Road is expected to carve out a unique path in the cell therapy field, creating sustainable growth value for investors [2]